Precision Medicine and Functional Genomics 2022
Biotech Forum
22 September 2022
Sidra Medicine, Hospital Auditorium
23-26 September 2022
St. Regis, Doha
Event Partner
Qatar Tourism
Educational Partners
Hamad Bin Khalifa University (HBKU)
SITC
Partnership Prospectus
DownloadDiamond Sponsors
Vodafone Qatar
QIC
QLM
Beema
MedTech
Zahrawi Group
BGI
Qatar Scientific Company
Platinum Sponsors
Sedeer Medical
Gold Sponsors
Kite Pharmaceutical
Vital Health Technologies
Silver Sponsor – Biotech Forum Only
Roche
Silver Sponsors
Cure Brain Cancer Foundation
AGBL
Future Health Biobank
Qatar Cancer Society
Integrated Gulf Biosystems
Sponsor’s Lunch Workshops
Diamond Sponsor | |||||
Company | Date | Time | Speaker | Talk Title | Synopsis |
BGI Genomics
To register kindly email Maria Brunsman mbrunsman@sidra.org |
24-Sep-22 | 13:20-13:50 | Chen Yue | Precision medicine in disease prevention and diagnosis | As the application of precision medicine in disease prevention and diagnosis had been widely used in the global community, this speech is going to introduce a closed-loop system from screening to solutions of diagnosis with the aim of covering every disease throughout the life cycle. |
Qatar Scientific
To register kindly email Maria Brunsman mbrunsman@sidra.org |
24-Sep-22 | 13:20-13:50 | Toby Huang, Regional Director – Middle East, MGI | Enabling More Accessible and Affordable Sequencing Solutions for Research and Clinical Applications on the MGI DNBSeq Platform | This talk will highlight MGI’s high throughput DNBSeq sequencing platforms and total solutions featuring automated sample preparation, sequencing, and bioinformatics analysis, from sample to report. Overview of both clinical diagnostics and personalized genomics applications for: whole genome, clinical whole exome, oncology, targeted panels, NIPT, PGS, and microbiome |
Titanium Sponsor | |||||
Company | Date | Time | Speaker | Talk Title | Synopsis |
Illumina
To register kindly email Maria Brunsman mbrunsman@sidra.org |
25-Sep-22 | 13:05-13:35 | Mr. Abdulelah Alissa, Senior Clinical Sales Specialist at Illumina | Introducing TruSight Oncology Comprehensive (EU), the first CE-marked IVD test kit for comprehensive genomic profiling. | Help inform targeted therapies for better patient outcomes. Conventional oncology testing approaches provide limited information and do not address all biomarkers in approved therapies and emerging immunotherapies. Furthermore, patients usually receive standard, non-matched regimens when a positive biomarker is not identified due to a lack of better options. With TruSight Oncology Comprehensive (EU), patients receive a comprehensive genomic profiling test, increasing their chances of being matched genomically with potentially more effective therapies and improved outcomes. |
Diamond Sponsor | |||||
Company | Date | Time | Speaker | Talk Title | Synopsis |
Al Zahrawi Medical
To register kindly email Maria Brunsman mbrunsman@sidra.org |
25-Sep-22 | 13:05-13:35 | Afif Abdel Nour, PhD | dPCR at the service of genomic research: what can we learn from the MIQE Guidelines? | In 2009, a group of qPCR experts published the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines for reproducible experiments. Those guidelines shaped present-day qPCR, which is considered a gold standard technique in molecular biology. Fast forward to 2013, dPCR also took advantage of the publication of the Minimum Information for Publication of Quantitative Digital PCR Experiments (dMIQE) guidelines to ensure global standardization. A new version of the dMIQE guidelines was published in 2020, considering the increasing number of applications and the introduction of new platforms. |
MEDTECH Corporation
To register kindly email Maria Brunsman mbrunsman@sidra.org |
26-Sep-22 | 13:05-13:35 | Ashan Musafer | The study of circulating tumor DNA: A ddPCR approach | The study of circulating tumor DNA (ctDNA) as a potential biomarker for the monitoring of response to treatment and identifying the emergence of drug resistance can come with many analytical hurdles. The key challenge is the requirement of a highly sensitive technique able to detect rare targets. In comes Droplet Digital PCR (ddPCR), a breakthrough technology that provides highly precise, ultrasensitive nucleic acid detection and quantification. In this talk, Mr. Ashan will introduce the use of ddPCR and its utility to study low abundant targets in complex backgrounds. |
QLM
To register kindly email Maria Brunsman mbrunsman@sidra.org |
26-Sep-22 | 13:05-13:35 | Jehad Rahima | QLM Company Profile and Services | Living a whole & healthy life is every human’s right and we at QLM ensure that every individual beneficiary covered by us is protected in a comprehensive manner and has timely access to the best Professional & Quality health care. We bring to you innovative and tailor-made insurance solutions coupled with a world class level of service. Our core strengths lie in a strong financial base, in-house 24/7 operations, highly qualified and motivated workforce with an in-depth knowledge of the local and international markets. Our diversified product range designed to provide premiere services furnished through a worldwide network of providers and patronized by millions over decades. Our Vision is to attain and retain customers with high-valued life & health insurance product services by giving them the most satisfying ownership experience wherever they may be. |